The prevention of oral mucositis in patients with blood cancers: Current concepts and emerging landscapes

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 10, Issue 4, 2012, Pages 362-375

  Niscola, Pasquale ^a   Tendas, Andrea ^b   Cupelli, Luca ^b   Catalano, Gianfranco ^b   Scaramucci, Laura ^b   Giovannini, Marco ^b   Trinchieri, Vito ^b   Sharma, Atul ^c   Efficace, Fabio ^d   Cartoni, Claudio ^b   Piccioni, Daniela ^e   Perrotti, Alessio ^e   Dentamaro, Teresa ^e   de Fabritiis, Paolo ^e   Keefe, Dorothy M K ^e  

^a S EUGENIO HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c INSTITUTE ROTARY CANCER HOSPITAL   (India)

^d Health Outcomes Research Unit of GIMEMA   (Italy)

^e UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Antineoplastic treatments; Chemotherapy; Hematology; Hematopoietic stem cell transplantation; Lactobacillus brevis CD2; Leukemia; Lymphoma; Mucositis; Multiple myeloma; Oral cavity; Palifermin; Prevention; Radiotherapy; Stomatitis

Indexed keywords

AMIFOSTINE; CARMUSTINE; CHLORHEXIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GLUCAGON LIKE PEPTIDE 2; GLUTAMINE; HISTONE DEACETYLASE; INTESTINAL TREFOIL FACTOR; LACTOFERRIN; MELPHALAN; METHIONINE; METHOTREXATE; PALIFERMIN; PILOCARPINE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; REACTIVE OXYGEN METABOLITE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; REPIFERMIN; SOMATOMEDIN; STANNOUS FLUORIDE; TRANSFORMING GROWTH FACTOR; UNINDEXED DRUG; VELAFERMIN;

CRYOTHERAPY; DRUG MEGADOSE; EDEMA; ERYTHEMA; GRAFT VERSUS HOST REACTION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LOW LEVEL LASER THERAPY; LOZENGE; MOUTH HYGIENE; NONHUMAN; ORAL MUCOSITIS; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; STOMATITIS; TASTE DISORDER; TOOTH DISCOLORATION;

FIBROBLAST GROWTH FACTOR 7; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MOUTH MUCOSA; STOMATITIS; TRANSPLANTATION CONDITIONING;

EID: 84870284637     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/187152512803530324     Document Type: Review

References (126)

1. Niscola, P. Mucositis in malignant hematology. Expert Rev., Hematol., 2010, 3(1), 57-65.
2. Sonis, S.T. The pathobiology of mucositis. Nat. Rev. Cancer, 2004, 4(4), 277-284.
3. Deshmukh, C.; Saikia, T.; Bakshi, A.; Amare-Kadam, P.; Baisane, C.; Parikh, P. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study. J. Assoc. Physicians India, 2005, 53, 291-295.
4. Keefe D.; Anthony L. Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care. Curr. Opin. Support. Palliat. Care, 2008, 2(1), 19-21.
5. Keefe, D.M. Intestinal mucositis: mechanisms and management. Curr. Opin. Oncol., 2007, 19(4), 323-327.
6. Niscola, P.; Romani, C.; Cupelli, L.; Scaramucci, L.; Tendas, A.; Dentamaro, T.; Amadori, S.; de Fabritiis, P. Mucositis in patients with hematologic malignancies: an overview. Haematologica, 2007, 92(2), 222-231.
7. Lalla, R.V.; Sonis, S.T.; Peterson, D.E. Management of oral mucositis in patients who have cancer. Dent. Clin. North Am., 2008, 52(1), 61-77.
8. Keefe, D.M.; Schubert, M.M.; Elting, L.S.; Sonis, S.T.; Epstein, J.B.; Raber-Durlacher, J.E.; Migliorati, C.A.; McGuire, D.B.; Hutchins, R.D.; Peterson, D.E. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer, 2007, 109(5), 820-831.
9. Bensinger, W.; Schubert, M.; Ang, K.K.; Brizel, D.; Brown, E.; Eilers, J.G.; Elting, L.; Mittal, B.B.; Schattner, M.A.; Spielberger, R.; Treister, N.S.; Trotti, A.M., 3rd. Prevention and management of mucositis in cancer care. J. Natl. Compr. Canc. Netw., 2008, 6 (Suppl. 1), 1-21.
10. Hensley, M.L.; Hagerty, K.L.; Kewalramani, T.; Green, D.M.; Meropol, N.J.; Wasserman, T.H.; Cohen, G.I.; Emami, B.; Gradishar, W.J.; Mitchell, R.B.; Thigpen, J.T.; Trotti, A. 3rd; von Hoff, D.; Schuchter, L.M. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol., 2009, 27(1),127-145.
11. Peterson, D.E.; Bensadoun, R.J.; Roila, F. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann. Oncol., 2010, 21(Suppl. 5), 261-265.
12. Worthington H.V.; Clarkson J.E.; Bryan G.; Furness S.; Glenny A.M.; Littlewood A.; McCabe M.G.; Meyer S.; Khalid T. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst. Rev., 2011, 13(4), CD000978.
13. Niscola, P.; Scaramucci, L.; Giovannini, M.; Ales, M.; Bondanini, F.; Cupelli, L.; Dentamaro, T.; Lamanda, M.; Natale, G.; Palumbo, R.; Romani, C.; Tendas, A.; Tolu, B.; Violo, L.; de Fabritiis, P. Palifermin in the management of mucositis in hematological malignancies: current evidences and future perspectives. Cardiovasc. Hematol. Agents Med. Chem., 2009, 7(4), 305-312.
14. Peterson, D.E.; Lalla, R.V. Oral mucositis: the new paradigms. Curr. Opin. Oncol., 2010, 22(4), 318-322.
15. Keefe, D.M.; Sonis, S.T.; Bowen, J.M. Emerging drugs for chemotherapy-induced mucositis. Expert Opin. Emerg. Drugs, 2008, 13(3), 511-522.
16. Wu, J.C.; Beale, K.K.; Ma, J.D. Evaluation of current and upcoming therapies in oral mucositis prevention. Future Oncol., 2010, 6(11), 1751-1770.
17. Micozzi, A.; Cartoni, C.; Monaco, M.; Martino, P.; Zittoun, R.; Mandelli, F. High incidence of infectious gastrointestinal complications observed in patients with acute myeloid leukemia receiving intensive chemotherapy for first induction of remission. Support. Care Cancer, 1996, 4, 294-297.
18. Niscola, P.; Romani, C.; Scaramucci, L.; Dentamaro, T.; Cupelli, L.; Tendas, A.; Piccioni, D.; Giovannini, M.; Tolu, B.; Cartoni, C.; Arcuri, E.; Perrotti, A.; Palumbo, R.; de Fabritiis, P. Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies. Bone Marrow Transplant., 2008, 41(9), 757-764.
19. Sonis, S.T.; Elting, L.S.; Keefe, D.; Peterson, D.E.; Schubert, M.; Hauer-Jensen, M.; Bekele, B.N.; Raber-Durlacher, J.; Donnelly, J.P.; Rubenstein, E.B. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer, 2004, 100(Suppl. 9), 1995-2025.
20. Sonis, S.T.; Oster, G.; Fuchs, H.; Bellm, L.; Bradford, W.Z.; Edelsberg, J.; Hayden, V.; Eilers, J.; Epstein, J.B.; LeVeque, F.G.; Miller, C.; Peterson, D.E.; Schubert, M.M.; Spijkervet, F.K.; Horowitz, M. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J. Clin. Oncol., 2001, 19(8), 2201-2205.
21. Chaimberg, K.H.; Cravero J.P. Mucositis and airway obstruction in a pediatric patient. Anesth. Analg., 2004, 99(1), 59-61.
22. Bellm, L.A.; Epstein, J.B.; Rose-Ped, A.; Martin, P.; Fuchs, H.J. Patient reports of complications of bone marrow transplantation. Support. Care Cancer, 2000, 8(1), 33-39.
23. Ozturk, M.; Komurcu, S.; Kilic, S.; Ozet, A.; Arpaci, F.; Ozturk, B.; Kuzhan,O.; Ataergin, S. Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. Support. Care Cancer, 2009, 17(10), 1295-1299.
24. Goldberg, J.; Jacobsohn, D.A.; Zahurak, M.L.; Vogelsang, G.B. Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease. Biol. Blood Marrow Transplant, 2005, 11, 101-107.
25. Woo, S.B.; Sonis, S.T.; Monopoli, M.M.; Sonis, A.L. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer, 1993, 72, 1612-1617.
26. McGuire D.B.; Altomonte V.; Peterson D.E.; Wingard J.R.; Jones R.J.; Grochow L.B. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol. Nurs Forum, 1993, 20, 1493-1502.
27. Grazziutti, M.L.; Dong, L.; Miceli, M.H.; Krishna, S.G.; Kiwan, E.; Syed, N.; Fassas, A.; van Rhee, F.; Klaus, H.; Barlogie, B.; Anaissie, E.J. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant., 2006, 38(7), 501-506.
28. Kashiwazaki, H.; Matsushita, T.; Sugita, J.; Shigematsu, A.; Kasashi, K.; Yamazaki, Y.; Kanehira, T.; Kondo, T.; Endo, T.; Tanaka, J.; Hashino, S.; Nishio, M.; Imamura, M.; Kitagawa, Y.; Inoue, N. A comparison of oral mucositis in allogeneic hematopoietic stem cell transplantation between conventional and reduced-intensity regimens. Support. Care Cancer, 2012, 20(5), 933-939.
29. Weiser, M.A.; O'Brien, S.; Thomas, D.A.; Pierce, S.A.; Lam, T.P.; Kantarjian, H.M. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Cancer, 2002, 94(2), 285-291.
30. Hueber, A.J.; Leipe, J.; Roesler, W.; Kalden, J.R.; Kallert, S.; Rech, J. Palifermin as treatment in dose-intense conventional polychemotherapy induced mucositis. Haematologica, 2006, 91(Suppl. 8), ECR32.
31. Mead, G.M.; Sydes, M.R.; Walewski, J.; Grigg, A.; Hatton, C.S.; Pescosta, N.; Guarnaccia, C.; Lewis, M.S.; McKendrick, J.; Stenning, S.P.; Wright, D. An international evaluation of CODOXM and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann. Oncol., 2002, 13(8), 1264-1274.
32. Schmidt, E.; Thoennissen, N.H.; Rudat, A.; Bieker, R.; Schliemann, C.; Mesters, R.M.; Zühlsdorf M.; Müller-Tidow, C.; Berdel, W.E. Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Ann. Oncol., 2008, 19(9), 1644-1649.
33. Pohlen, M.; Gerth, H.U.; Liersch, R.; Koschmieder, S.; Mesters, R.M.; Kessler, T.; Appelmann, I.; Müller-Tidow, C.; Berdel, W.E. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma. Am. J. Hematol., 2011, 86(12),61-64.
34. Dumontet, C.; Landi, S.; Reiman, T.; Perry, T.; Plesa, A.; Bellini, I.; Barale, R.; Pilarski, L.M.; Troncy, J.; Tavtigian, S.; Gemignani, F. Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. Bone Marrow Transplant., 2010, 45(8), 1316-1324.
35. Gibson, R.J.; Bowen, J.M.; Keefe, D.M. Technological advances in mucositis research: New insights and new issues. Cancer Treat. Rev., 2008, 34(5), 476-482.
36. Quinn, B.; Potting, C.M.; Stone, R.; Blijlevens, N.; Fliedner, M.; Margulies, A.; Sharp, L. Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients. Eur. J. Cancer, 2008, 44(1), 61-72.
37. No authors listed. WCCNR. Assessing stomatitis: refinement of the Western Consortium for Cancer Nursing Research (WCCNR) stomatitis staging system. Can. Oncol. Nurs. J., 1998, 8, 160-165.
38. McGuire, D.B.; Peterson, D.E.; Muller, S.; Owen, D.C.; Slemmons, M.F.; Schubert, M.M. The 20 item oral mucositis index: reliability and validity in bone marrow and stem cell transplant patients. Cancer Invest., 2002, 20, 893-903.
39. Bhatt, V.; Vendrell, N.; Nau, K.; Crumb, D.; Roy, V. Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation. J. Oncol. Pharm. Pract., 2010, 16(3), 195-204.
40. Santos P.S.; Coracin F.L.; Barros J.C.; Dulley F.L.; Nunes F.D.; Magalhães M.G. Impact of oral care prior to HSCT on the severity and clinical outcomes of oral mucositis. Clin. Transplant., 2011, 25(2), 325-328.
41. McGuire D.B.; Correa M.E.; Johnson J.; Wienandts P. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support. Care Cancer, 2006, 14(6), 541-547.
42. Kashiwazaki, H.; Matsushita, T.; Sugita, J.; Shigematsu, A.; Kasashi, K.; Yamazaki, Y.; Kanehira, T.; Yamamoto, S.; Kondo, T.; Endo, T.; Tanaka, J.; Hashino, S.; Nishio, M.; Imamura, M.; Kitagawa, Y.; Inoue, N. Professional oral health care reduces oral mucositis and febrile neutropenia in patients treated with allogeneic bone marrow transplantation. Support. Care Cancer, 2012, 20(2), 367-373.
43. Lilleby, K.; Garcia, P.; Gooley, T.; McDonnnell, P.; Taber, R.; Holmberg, L.; Maloney, D.G.; Press, O.W.; Bensinger, W. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant., 2006, 37(11),1031-1035.
44. Mori, T.; Aisa, Y.; Yamazaki, R.; Mihara, A.; Ikeda, Y.; Okamoto, S. Cryotherapy for the prevention of high-dose melphalaninduced oral mucositis. Bone Marrow Transplant., 2006, 38(9), 637-638.
45. Mori, T.; Yamazaki, R.; Aisa, Y.; Nakazato, T.; Kudo, M.; Yashima, T.; Kondo, S.; Ikeda, Y.; Okamoto, S. Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support. Care Cancer, 2006, 14(4), 392-395.
46. Migliorati, C.A.; Oberle-Edwards, L.; Schubert, M. The role of alternative and natural agents, cryotherapy, and/or laser for management of alimentary mucositis. Support. Care Cancer, 2006, 14, 533-540.
47. Meloni G.; Capria S.; Proia A.; Trisolini S.M.; Mandelli F. Ice pops to prevent melphalan-induced stomatitis. Lancet, 1996, 347(9016), 1691-1692.
48. Mori, T.; Hasegawa, K.; Okabe, A.; Tsujimura, N.; Kawata, Y.; Yashima, T.; Kobayashi, N.; Kondo, S.; Aisa, Y.; Kato, J.; Tsunoda, K.; Nagai, T.; Nakagawa, T.; Shigematsu, N.; Kubo, A.; Ikeda, Y.; Okamoto, S. Efficacy of mouth rinse in preventing oral mucositis in patients receiving high-dose cytarabine for allogeneic hematopoietic stem cell transplantation. Int. J. Hematol., 2008, 88(5), 583-587.
49. Gori, E.; Arpinati, M.; Bonifazi, F.; Errico, A.; Mega, A.; Alberani, F.; Sabbi, V.; Costazza, G.; Leanza, S.; Borrelli, C.; Berni, M.; Feraut, C.; Polato, E.; Altieri, M.C.; Pirola, E.; Loddo, M.C.; Banfi, M.; Barzetti, L.; Calza, S.; Brignoli, C.; Bandini, G.; De Vivo, A.; Bosi, A.; Baccarani, M. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate-and nonmethotrexate-containing graft-versus-host disease prophylaxis regimens. Bone Marrow Transplant., 2007, 39(6), 347-352.
50. Cowen, D.; Tardieu, C.; Schubert, M.; Peterson, D.; Resbeut, M.; Faucher, C.; Franquin, J.C. Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int. J. Radiat. Oncol. Biol. Phys., 1997, 38(4), 697-703.
51. Barasch, A.; Peterson, D.E.; Tanzer, J.M.; D'Ambrosio, J.A.; Nuki, K.; Schubert, M.M.; Franquin, J.C.; Clive, J.; Tutschka, P. Heliumneon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer, 1995, 76(12), 2550-2556.
52. Chor, A.; Torres, S.R.; Maiolino, A.; Nucci, M. Low-power laser to prevent oral mucositis in autologous hematopoietic stem cell transplantation. Eur. J. Haematol., 2010, 84(2), 178-179.
53. Antunes, H.S.; de Azevedo, A.M.; da Silva Bouzas, L.F.; Adão, C.A.; Pinheiro, C.T.; Mayhe, R.; Pinheiro, L.H.; Azevedo, R.; D'Aiuto de Matos, V.; Rodrigues, P.C.; Small, I.A.; Zangaro, R.A.; Ferreira, C.G. Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial. Blood, 2007, 109(5), 2250-2255.
54. Schubert, M.M.; Eduardo, F.P.; Guthrie, K.A.; Franquin, J.C.; Bensadoun, R.J.; Migliorati, C.A.; Lloid, C.M.; Eduardo, C.P.; Walter, N.F.; Marques, M.M.; Hamdi, M. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support. Care Cancer, 2007, 15(10), 1145-1154.
55. Jaguar, G.C.; Prado, J.D.; Nishimoto, I.N.; Pinheiro, M.C.; de Castro, D.O., Jr.; da Cruz Perez, D.E.; Alves, F.A. Low-energy laser therapy for prevention of oral mucositis in hematopoietic stem cell transplantation. Oral Dis., 2007, 13(6), 538-543.
56. Silva, G.B.; Mendonça, E.F.; Bariani, C.; Antunes, H.S.; Silva, M.A. The prevention of induced oral mucositis with low-level laser therapy in bone marrow transplantation patients: a randomized clinical trial. Photomed. Laser Surg., 2011, 29(1), 27-31.
57. Hofmeister, C.C.; Stiff, P.J. Mucosal protection by cytokines. Curr. Hematol. Rep., 2005, 4,446-453.
58. von Bültzingslöwen, I.; Brennan, M.T.; Spijkervet, F.K.; Logan, R.; Stringer, A.; Raber-Durlacher, J.E.; Keefe, D. Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support. Care Cancer, 2006, 14(6), 519-527.
59. van der Lelie, H.; Thomas, B.L.; van Oers, R.H.; Ek-Post, M.; Sjamsoedin, S.A.; van Dijk-Overtoom, M.L.; Timmer, J.G.; von dem Borne, A.E. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Ann. Hematol., 2001, 80(3), 150-154.
60. Dazzi, C.; Cariello, A.; Giovanis, P.; Monti, M.; Vertogen, B.; Leoni, M.; Tienghi, A.; Turci, D.; Rosti, G.; Nanni, O.; Rondoni, C.; Marangolo, M. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Ann. Oncol., 2003, 14(4), 559-563.
61. Beck, P.L.; Wong, J.F.; Li Y.; Swaminathan, S.; Xavier, R.J.; Devaney, K.L.; Podolsky, D.K. Chemotherapy-and radiotherapyinduced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology, 2004, 126(3), 796-808.
62. Caluwaerts, S.; Vandenbroucke, K.; Steidler, L.; Neirynck, S.; Vanhoenacker, P.; Corveleyn, S.; Watkins, B.; Sonis, S.; Coulie, B.; Rottiers, P. AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral. Oncol., 2010, 46(7), 564-570.
63. Peterson, D.E.; Barker, N.P.; Akhmadullina, L.I.; Rodionova, I.; Sherman, N.Z.; Davidenko, I.S.; Rakovskaya, G.N.; Gotovkin, E.A.; Shinkarev, S.A.; Kopp, M.V.; Kulikov, E.P.; Moiseyenko, V.M.; Gertner, J.M.; Firsov, I.; Tuleneva, T.; Yarosh, A.; Woon, C.W. Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. J. Clin. Oncol., 2009, 27(26), 4333-4338.
64. Girdler, N.M.; McGurk, M.; Aqual, S.; Prince, M. The effect of epidermal growth factor mouthwash on cytotoxic-induced oral ulceration. A Phase I clinical trial. Am. J. Clin. Oncol., 1995, 18(5), 403-406.
65. Wu, H.G.; Song, S.Y.; Kim, Y.S.; Oh, Y.T.; Lee, C.G.; Keum, K.C.; Ahn, Y.C.; Lee, S.W. Therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective Phase 2 multi-institutional clinical trial. Cancer, 2009, 115(16), 3699-3708.
66. Schuster, M.W.; Shore, T.B.; Harpel, J.G.; Greenberg, J.; Jalilizeinali, B.; Possley, S.; Gerwien, R.W.; Hahne, W.; Halvorsen, Y.D. Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant. Support. Care Cancer, 2008, 16(5), 477-483.
67. Hunter, A.; Mahendra, P.; Wilson, K.; Fields, P.; Cook, G.; Peniket, A.; Crawley, C.; Hickling, R.; Marcus, R. Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebocontrolled trial. Bone Marrow Transplant., 2009, 43(7), 563-569.
68. Zhao, J.; Kim, K.A.; De Vera, J.; Palencia, S.; Wagle, M.; Abo, A. R-spondin 1 protects mice from chemotherapy or radiation-induced oral mucositis through the canonical wnt/b-catenin pathway. Proc. Natl. Acad. Sci. USA, 2009, 106(7), 2331-2336.
69. Auf demKeller, U.; Krampert, M.; Kümin, A.; Braun, S.; Werner, S. Keratinocyte growth factor: effects on keratinocytes and mechanisms of action. Eur. J. Cell Biol., 2004, 83(11-12), 607-612.
70. Blijlevens, N.; Sonis, S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy-and radiotherapyinduced mucositis. Ann. Oncol., 2007, 18(5), 817-826.
71. Barasch, A.; Epstein, J.; Tilashalski, K. Palifermin for management of treatment-induced oral mucositis in cancer patients. Biologics, 2009, 3, 111-116.
72. Athar, U.; Gentile, T.C. Keratinocyte growth factor. Expert Opin. Biol. Ther., 2009, 9(6), 779-787.
73. Weigelt, C.; Haas, R.; Kobbe, G. Pharmacokinetic evaluation of palifermin for mucosal protection from chemotherapy and radiation. Expert Opin. Drug Metab. Toxicol., 2011, 7(4), 505-515.
74. Spielberger, R.; Stiff, P.; Bensinger, W.; Gentile, T.; Weisdorf, D.; Kewalramani, T.; Shea, T.; Yanovich, S.; Hansen, K.; Noga, S.; McCarty, J.; LeMaistre, C.F.; Sung, E.C.; Blazar, B.R.; Elhardt, D.; Chen, M.G.; Emmanouilides, C. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med., 2004, 351(25), 2590-2598.
75. Stiff, P.J.; Emmanouilides, C.; Bensinger, W.I.; Gentile, T.; Blazar, B.; Shea, T.C.; Lu, J.; Isitt, J.; Cesano, A.; Spielberger, R. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J. Clin. Oncol., 2006, 24(33), 5186-5193.
76. Keefe, D.; Lees, J.; Horvath, N. Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience. Support. Care Cancer, 2006, 14(6), 580-582.
77. Rzepecki, P.; Sarosiek, T.; Barzal, J.; Oborska, S.; Nurzynski, P.; Wasko, A.; Szczylik, C. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation-single centre experience. J. BUON, 2007, 12(4), 477-482.
78. Nasilowska-Adamska, B.; Rzepecki, P.; Manko, J.; Czyz, A.; Markiewicz, M.; Federowicz, I.; Tomaszewska, A.; Piatkowska-Jakubas, B.; Wrzesien-Kus, A.; Bieniaszewska, M.; Duda, D.; Szydlo, R.; Halaburda, K.; Szczepinski, A.; Lange, A.; Hellman, A.; Robak, T.; Skotnicki, A.; Jedrzejczak, W.W.; Walewski, J.; Holowiecki, J.; Komarnicki, M.; Dmoszynska, A.; Warzocha, K.; Marianska, B. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant., 2007, 40(10), 983-988.
79. Langner, S.; Staber, P.; Schub, N.; Gramatzki, M.; Grothe, W.; Behre, G.; Rabitsch, W.; Urban, C.; Linkesch, W.; Neumeister, P. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant., 2008, 42(4), 275-279.
80. Verhagen, M.P.; Wondergem, M.J.; Visser, O. Palifermin dose should be adjusted to different therapy regimens. Bone Marrow Transplant., 2009, 43(8), 665.
81. Kobbe, G.; Bruns, I.; Schroeder, T.; Czibere, A.; Warnecke, J.; Hieronimus, N.; Safaian, N.; Kondakci, M.; Saure, C.; Germing, U.; Haas, R.; Fenk, R. A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Ann. Oncol., 2010, 21(9), 1898-1904.
82. Campbell, P.; Friebe, A.; Foulstone, P.; Grigg, A.; Hempton, J.; Bajel, A. Impact of palifermin on mucosal toxicity in autologous stem cell transplants using busulfan-melphalan conditioning chemotherapy for Hodgkin and non-Hodgkin lymphoma. Leuk. Lymphoma, 2012 [Epub ahead of print].
83. Elting, L.S.; Shih, Y.C.; Stiff, P.J.; Bensinger, W.; Cantor, S.B., Cooksley, C., Spielberger, R.; Emmanoulides, C. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. Biol. Blood Marrow Transplant., 2007, 13(7), 806-813.
84. Nasilowska-Adamska, B.; Szydlo, R.; Rzepecki, P.; Czyz, A.; Tomaszewska, A.; Markiewicz, M.; Torosian, T.; Bieniaszewska, M.; Hellman, A.; Jedrzejczak, W.W.; Holowiecki, J.; Komarnicki, M.; Warzocha, K.; Marianska, B. Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT. Ann. Transplant., 2011, 16(4), 47-54.
85. Tareen M.; Grossman M.E. Images in clinical medicine. White tongue. N. Engl. J. Med., 2009, 360(20), e26.
86. Sibelt, L.A.; Aboosy, N.; van der Velden, W.J.; Blijlevens, N.M.; Blokx, W.A.; Seyger, M.M. Palifermin-induced flexural hyperpigmentation: a clinical and histological study of five cases. Br. J. Dermatol., 2008, 159(5), 1200-1203.
87. Keijzer, A.; Huijgens, P.C.; van de Loosdrecht, A.A. Palifermin and palmar-plantar erythrodysesthesia. Br. J. Haematol., 2007, 136(6), 856-857.
88. Grzegorczyk-Jawiska, A.; Kozak, I.; Karakulska-Prystupiuk, E.; Rokicka, M.; Ganowicz, E.; Dwilewicz-Trojaczek, J.; Górska, R. Transient oral cavity and skin complications after mucositis preventing therapy (palifermin) in a patient after allogeneic PBSCT. Case history. Adv. Med. Sci., 2006, 51(Suppl. 1), 66-68.
89. Kaloyannidis, P.; Papalexandri, A.; Papaemanouil, E.; Papaioannou, M.; Sakellari, I. Reversible painful oral mucosal hyperpigmentation following palifermin administration. Acta Haematol., 2010, 124(3), 185-187.
90. Lee, M.; Grassi, M. Acanthosis nigricans in a patient treated with palifermin. Cutis, 2010, 86(3), 136-137.
91. Barasch, A.; Elad, S.; Altman, A.; Damato, K.; Epstein, J. Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Support. Care Cancer, 2006, 14(6), 528-532.
92. Lalla, R.V.; Schubert, M.M.; Bensadoun, R.J.; Keefe, D. Antiinflammatory agents in the management of alimentary mucositis. Support. Care Cancer, 2006, 14, 558-565.
93. Potting, C.M.; Uitterhoeve, R.; Op Reimer, W.S.; Van Achterberg, T. The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review. Eur. J. Cancer Care (Engl), 2006, 15(5), 431-439.
94. Vokurka, S.; Bystrická, E.; Koza, V.; Scudlová, J.; Pavlicová, V.; Valentová, D.; Bocková, J.; Misaniová, L. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT-results of a randomized multicentre study. Support. Care Cancer, 2005, 13(7), 554-558.
95. Dodd, M.J.; Dibble, S.L.; Miaskowski, C.; MacPhail, L.; Greenspan, D.; Paul, S.M.; Shiba, G.; Larson, P. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 2000, 90(1), 39-47.
96. Pitten, F.A.; Kiefer, T.; Buth, C.; Doelken, G.; Kramer, A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. J. Hosp. Infect., 2003, 53(4), 283-291.
97. Lövenich, H.; Schütt-Gerowitt, H.; Keulertz, C.; Waldschmidt, D.; Bethe, U.; Söhngen, D.; Cornely, O.A. Failure of anti-infective mouth rinses and concomitant antibiotic prophylaxis to decrease oral mucosal colonization in autologous stem cell transplantation. Bone Marrow Transplant., 2005, 35(10), 997-1001.
98. Sironi, M.; Milanese, C.; Vecchi, A.; Polenzani, L.; Guglielmotti, A.; Coletta, I., Landolfi, C.; Soldo, L.; Mantovani, A.; Pinza, M. Benzydamine inhibits the release of tumor necrosis factor-alpha and monocyte chemotactic protein-1 by Candida albicansstimulated human peripheral blood cells. Int. J. Clin. Lab Res., 1997, 27(2), 118-122.
99. Yuen, K.Y.; Woo, P.C.; Tai, J.W.; Lie, A.K.; Luk, J.; Liang, R. Effects of clarithromycin on oral mucositis in bone marrow transplant recipients. Haematologica, 2001, 86, 554-555.
100. Elad, S.; Ackerstein, A.; Bitan, M.; Shapira, M.Y.; Resnick, I.; Gesundheit, B.; Cohen, Y.; Diss, O.; Barak, D.; Dray, L.; Or, R. A prospective, double-blind phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation. Bone Marrow Transplant., 2006, 37(8), 757-762.
101. Lockhart, P.B.; Brennan, M.T.; Kent, M.L.; Packman, C.H.; Norton, H.J.; Fox, P.C.; Frenette, G. Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplant., 2005, 35(7), 713-720.
102. Sugita, J.; Matsushita, T.; Kashiwazaki, H.; Kosugi, M.; Takahashi, S.; Wakasa, K.; Shiratori, S.; Ibata, M.; Shono, Y.; Shigematsu, A.; Obara, M.; Fujimoto, K.; Endo, T.; Nishio, M.; Kondo, T.; Hashino, S.; Tanaka, J.; Asaka, M.; Imamura, M. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD. Bone Marrow Transplant., 2011, 47(2), 258-264.
103. Aquino, V.M.; Harvey, A.R.; Garvin, J.H.; Godder, K.T.; Nieder, M.L.; Adams, R.H.; Jackson, G.B.; Sandler, E.S. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant., 2005, 36(7), 611-616.
104. Crowther, M.; Avenell, A.; Culligan, D.J. Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation. Bone Marrow Transplant., 2009, 44(7), 413-425.
105. Papas, A.S.; Clark, R.E.; Martuscelli, G.; O'Loughlin, K.T.; Johansen, E.; Miller, K.B. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant., 2003, 31(8), 705-712.
106. Wako-Grabowska, A.; Rzepecki, P.; Oborska, S.; Barza, J.; Gawro ski, K.; Mot, B.; Szczylik, C. Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience. Transplant. Proc., 2011, 43(8), 3111-3113.
107. Oguchi, M.; Shikama, N.; Sasaki, S.; Gomi, K.; Katsuyama, Y.; Ohta, S.; Hori, M.; Takei, K.; Arakawa, K.; Sone, S. Mucosaadhesive water-soluble polymer film for treatment of acute radiation-induced oral mucositis. Int. J. Radiat. Oncol. Biol. Phys., 1998, 40(5), 1033-1037.
108. Buchsel, P.C. Polyvinylpyrrolidone-sodium hyaluronate gel (Gelclair): a bioadherent oral gel for the treatment of oral mucositis and other painful oral lesions. Expert Opin. Drug Metab. Toxicol., 2008, 4(11),1449-1454.
109. Vokurka, S.; Skardova, J.; Hruskova, R.; Kabatova-Maxova, K.; Svoboda, T.; Bystricka, E.; Steinerova, K.; Koza, V. The effect of polyvinylpyrrolidone-sodium hyaluronate gel (Gelclair) on oral microbial colonization and pain control compared with other rinsing solutions in patients with oral mucositis after allogeneic stem cells transplantation. Med. Sci. Monit., 2011, 17(10), CR572-576.
110. Santini, V. Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opin. Pharmacother., 2001, 2(3), 479-489.
111. Capelli, D.; Santini, G.; De Souza, C.; Poloni, A.; Marino, G.; Montanari, M.; Lucesole, M.; Brunori, M.; Massidda, D.; Offidani, M.; Leoni, P.; Olivieri, A. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br. J. Haematol., 2000, 110(2), 300-307.
112. Hartmann, J.T.; von Vangerow, A.; Fels, L.M.; Knop, S.; Stolte, H.; Kanz, L.; Bokemeyer, C. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Br. J. Cancer, 2001, 84(3), 313-320.
113. Thieblemont, C.; Dumontet, C.; Saad, H.; Roch, N.; Bouafia, F.; Arnaud, P.; Hequet, O.; Espinouse, D.; Salles, G.; Roy, P.; Eljaafari-Corbin, A.; Du Manoir-Baumgarten, C.; Coiffier, B. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant., 2002, 30(11), 769-775.
114. Spencer, A.; Horvath, N.; Gibson, J.; Prince, H.M.; Herrmann, R.; Bashford, J.; Joske, D.; Grigg, A.; McKendrick, J.; Prosser, I.; Lowenthal, R.; Deveridge, S.; Taylor, K. Australasian Leukemia and Lymphoma Group. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant., 2005, 35(10), 971-977.
115. Benesch, M.; McDonald, G.B.; Schubert, M.; Appelbaum, F.R.; Deeg, H.J. Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study. Bone Marrow Transplant., 2003, 32(11), 1071-1075.
116. Hwang, W.Y.; Koh, L.P.; Ng, H.J.; Tan, P.H.; Chuah, C.T.; Fook, S.C.; Chow, H.; Tan, K.W.; Wong, C.; Tan, C.H.; Goh, Y.T. A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant., 2004, 34(1), 51-6.
117. Sharma, A.; Rath, G.K.; Chaudhary, S.P.; Thakar, A.; Mohanti, B.K.; Bahadur, S. Lactobacillus brevis CD2 lozenges reduce radiation-and chemotherapy-induced mucositis in patients with head and neck cancer: A randomizd double-blind placebocontrolled study. Eur. J. Cancer, 2012, 48(6), 875-881.
118. Chung, Y.L.; Lee, M.Y.; Pui, N.N. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis, 2009, 30(8), 1387-1397.
119. Hamstra, D.A.; Eisbruch, A.; Naidu, M.U.; Ramana, G.V.; Sunkara, P.; Campbell, K.C.; Ross, B.D.; Rehemtulla, A. Pharmacokinetic analysis and phase 1 study of MRX-1024 in patients treated with radiation therapy with or without cisplatinum for head and neck cancer. Clin. Cancer Res., 2010, 16(9), 2666-2676.
120. Riccia, D.N.; Bizzini, F.; Perilli, M.G.; Polimeni, A.; Trinchieri, V.; Amicosante, G.; Cifone, M.G. Anti-inflammatory effects of Lactobacillus brevis (CD2) on periodontal disease. Oral Dis., 2007, 13(4), 376-385.
121. Tasli, L.; Mat, C.; De Simone, C.; Yazici, H. Lactobacilli lozenges in the management of oral ulcers of Behçet's syndrome. Clin. Exp. Rheumatol., 2006, 24(5 Suppl. 42), S83-86.
122. Niscola, P.; Tendas, A.; Scaramucci, L.; Giovanni, M.; Trinchieri, V.; De Fabritiis, P. Aphthous oral ulceration and its successful management by Lactobacillus brevis CD2 extract in an adult haemophilic patient. Haemophilia, 2012, 18(3), e78-79.
123. Hahn, T.; Zhelnova, E.; Sucheston, L.; Demidova, I.; Savchenko, V.; Battiwalla, M.; Smiley, S.L.; Ambrosone, C.B.; McCarthy, P.L., Jr. A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow transplantation. Biol. Blood Marrow Transplant., 2010, 16(6), 801-808.
124. Bogunia-Kubik, K.; Polak, M.; Lange, A. TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant., 2003, 32(6),617-622.
125. Quinn, B.; Stone, R.; Uhlenhopp, M.; McCann, S.; Blijlevens, N. Ensuring accurate oral mucositis assessment in the European Group for Blood and Marrow Transplantation Prospective Oral Mucositis Audit. Eur. J. Oncol. Nurs., 2007, 11 (Suppl. 1), 10-18.
126. Stone, R.; Potting, C.M.; Clare, S.; Uhlenhopp, M.; Davies, M.; Mank, A.; Quinn, B.; Research Subgroup of European Group for Blood and Marrow Transplantation Nurses Group (EBMT-NG). Management of oral mucositis at European transplantation centres. Eur. J. Oncol. Nurs., 2007, 11(Suppl. 1), S3-9.